CLL incidence and prevalence have decreased globally, but regional disparities exist, with high-SDI regions seeing declines and low-SDI regions experiencing stable or increasing rates. Mortality ...

Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

(RTTNews) - BeOne Medicines Ltd. (ONC) Thursday announced it presented new clinical data at the 2025 European Hematology Association or EHA Congress, highlighting the potential of its next-generation ...

Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...

Zanubrutinib is currently best-in-class among BTK inhibitors for CLL, with superior efficacy and safety over ibrutinib and strong market momentum. Zanubrutinib will be in the leading position in CLL ...